ASTH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Astrana Health Inc (ASTH) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. Despite strong revenue growth and a positive outlook for 2026, the stock faces significant challenges, including ineffective internal controls, declining net income, and a negative recent price trend. Holding off for clearer positive signals or improved financial stability would be prudent.
The technical indicators show mixed signals. The MACD is positive but contracting, RSI is neutral at 67.424, and moving averages are converging. The stock is trading below its previous close, and key support levels are at $19.61, with resistance at $25.515. The recent price trend is negative, with a -2.03% regular market change and a -4.03% post-market change.
Strong revenue growth: Q4 2025 revenue increased 42.89% YoY, and FY 2025 revenue grew 56% YoY.
Positive 2026 revenue guidance of $3.8 billion to $4.1 billion.
Analysts maintain a Buy rating, citing long-term growth potential in value-based care and organic market opportunities.
Ineffective internal controls over financial reporting as of December 31,
Net income dropped significantly (-186.30% YoY) in Q4 2025, and EPS declined by -180%.
Recent price trend is negative, with a -2.03% regular market change and -4.03% post-market change.
Stock trend analysis suggests further declines in the short term (-2.8% in the next week, -6.04% in the next month).
Astrana Health reported strong revenue growth in Q4 2025 (42.89% YoY) and FY 2025 (56% YoY). However, net income dropped significantly (-186.30% YoY), and EPS declined by -180%. Gross margin improved by 29.83% YoY to 8.27%. Despite revenue growth, profitability metrics are concerning.
Analysts maintain a Buy rating but have lowered price targets. BTIG reduced its target from $45 to $40, citing macro challenges and the need for favorable 2026 guidance. Needham initiated coverage with a $28 target, highlighting long-term growth potential in value-based care and organic market opportunities.
